AI assistant
Spero Therapeutics, Inc. — Director's Dealing 2017
Nov 1, 2017
34087_dirs_2017-11-01_89fee836-5da9-4930-8adb-1c0a118ff532.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Spero Therapeutics, Inc. (SPRO)
CIK: 0001701108
Period of Report: 2017-11-01
Reporting Person: VINK PATRICK V.J.J. (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $5.90 | 2027-07-05 | Common Stock (4475) | Direct | |
| Stock Option (Right to Buy) | $5.90 | 2027-07-05 | Common Stock (4803) | Direct | |
| Stock Option (Right to Buy) | $5.90 | 2027-07-05 | Common Stock (21236) | Direct |
Footnotes
F1: The shares underlying this option vested as to 25% on August 24, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
F2: The number of underlying shares of common stock and the exercise price reported reflect a 1-for-6.0774 reverse stock split of the Issuer's common stock effected on October 20, 2017.
F3: The shares underlying this option vested as to 25% on May 13, 2017, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
F4: The shares underlying this option vest as to 25% on July 6, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.